Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours

Bibliography

• FRANKS LM: What is cancer? In: Introduction to the Cellular and Molecular Biology of Cancer. Franks LM, Teich NM (Eds), Oxford University Press, London (1997):1–20.
   Google Scholar
• HART IR: The spread of tumours. In: Introduction to the Cellular and Molecular Biology of Cancer. Franks LM, Teich NM (Eds), Oxford University Press, London (1997):21–33.
   Google Scholar
• BRIGGER I, DUBERNET C, COUVREUR P: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. (2002) 54:631–651.
   PubMed Web of Science ®Google Scholar
• DUNCAN R: Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as common gateway? Pharm. Sci. TechnoL Today (1999) 2(11):441–449.
   PubMedGoogle Scholar
• BABAN DF, SEYMOUR LW: Control of tumour vascular permeability. Adv. Drug Deliv. Rev. (1998) 34(1):109–119.
   PubMed Web of Science ®Google Scholar
• OGRIS M, WAGNER E: Targeting tumours with non-viral gene delivery systems. Drug Discov. Today (2002) 7(8):479–485.
   PubMed Web of Science ®Google Scholar
• BRANNON-PEPPAS L, BLANCHETTE JO: Nanoparticles and targeted systems for cancer therapy. Adv. DrugDeliv. Rev. (2004) 56:1649–1659.
   PubMed Web of Science ®Google Scholar
• •This paper describes the possibilities of using NPs in the treatment of cancer.
   Google Scholar
• FENG S, CHIEN S: Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other disease. Chem. Engin. Sci. (2003) 58(18):4087–4114.
   Web of Science ®Google Scholar
• GELDERBLOM H, VERWEIJ J, NOOTER K, SPARREBOOM A: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer (2001) 7:1590–1598.
   Web of Science ®Google Scholar
• SINGLA AK, GARG A, AGGARWAL D:Paclitaxel and its formulations. Int. J. Pharm. (2002) 235:179–192.
   PubMed Web of Science ®Google Scholar
• STOUCH TR, GUDMUNDSSON O: Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. (2002) 54:315–328.
   PubMed Web of Science ®Google Scholar
• TORCHILIN VP, LUKYANOV AN: Peptide and protein drug delivery to and into tumours: challenges and solutions. Drug Discov. Today (2003) 8(6):259–266.
   PubMed Web of Science ®Google Scholar
• HANS ML, LOWMAN AM: Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. (2002) 6:319–327.
   Web of Science ®Google Scholar
• PANYAM J, LABHASETWAR V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. (2003) 55:329–347.
   PubMed Web of Science ®Google Scholar
• SONG CX, LABHASETWAR MURPHY H et al.: Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J. Control. Rel. (1997) 43:197–212.
   Google Scholar
• JUNG T, KAMM W, BREITENBACH A, KAISERLING E, XIAO JX, KISSEL T: Biodegradible nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. (2000) 50:147–160.
   Google Scholar
• MCCLEAN S, PROSSER E, MEEHAN E et al.: Binding and uptake of biodegradible poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur. j Pharm. Sci. (1998) 6:153–163.
   PubMed Web of Science ®Google Scholar
• PRABHA S, ZHOU WZ, PANYAM J, LABHASETWAR V: Size-dependancy of nanoparticle-mediated gene transfection: studies with fractionated nanoparticle. Int. J. Pharm. (2002) 244:105–115.
   PubMed Web of Science ®Google Scholar
• DESAI MP, LABHASETWAR V, AMIDON GL, LEVY RJ: Gastrointestinal uptake of biodegradible microparticles: effect of particle size. Pharm. Res. (1996) 13:1838–1845.
   PubMed Web of Science ®Google Scholar
• YIN WIN K, FENG S-S: Effect of particlesize and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 26:2713–2711.
   PubMed Web of Science ®Google Scholar
• MAEDA H, MATSUMURA Y: Tumouritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. (1989) 6:193–210.
   PubMed Web of Science ®Google Scholar
• YUAN F, DELLIAN M, FUKUMURA D et al.: Vascular permeability in a human tumour xenograft: molecular size dependance and cutoff size. Cancer Res. (1995) 55:3752–3756.
   PubMed Web of Science ®Google Scholar
• DUNCAN R: The dawning era of polymer therapeutics. Nature Rev. (2003) 2:347–360.
   Web of Science ®Google Scholar
• ••An interesting review that discusses theapplication of polymer therapeutics.
   Google Scholar
• SALTZMAN WM, FUNG LK: Polymeric implants for cancer therapy and diagnosis. Adv. Drug Deliv. Rev. (1997) 26:209–230.
   PubMed Web of Science ®Google Scholar
• JAIN JP, MODI S, DOMB AJ, KUMAR N: Role of polyanhidridesas localized drug carriers. J. Control. Release (2005) 103(3):541–563.
   PubMed Web of Science ®Google Scholar
• SINHA VR, TREHAN A: Biodegradable microspheres for protein delivery. J. Control. Release (2003) 90:261–280.
   PubMed Web of Science ®Google Scholar
• WHITTLESEY KJ, SHEA LD: Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface. Exp. NeuroL (2004) 190:1–16.
   PubMed Web of Science ®Google Scholar
• LI C: Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. (2002) 54:695–713.
   PubMed Web of Science ®Google Scholar
• SAHOO SK, LABHASETWAR V: Nanotech approach to drug delivery and imaging. Drug Discov. Today (2003) 8(24):1112–1120.
   PubMed Web of Science ®Google Scholar
• WHITE NS, ERRINGTON RJ. Fluorescence techniques for drug delivery research: theory and practice. Adv. Drug Deliv. Rev. (2005) 57(1,2):17–42.
   Google Scholar
• QUINTANAR-GUERRERO D, ALLEMANN E, FESSI H et al.: Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymes. Drug Dev. Ind. Pharm. (1998) 24(12):1113–1128.
   PubMed Web of Science ®Google Scholar
• ALLEMANN E, GURNY R, DOELKER E: Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. (1993) 39(5):173–191.
   Web of Science ®Google Scholar
• VAUTHIER-HOLTZSCHERER C, BENABBOU S, SPENLEHAUER G et al.: Methodology for the preparation of ultra-dispersed polymer systems. STP Pharm. (1991) 1(2):109–116.
   Google Scholar
• KREUTER J: Nanoparticles. In: Encyclopedia of Pharmaceuticcal Technology Swarbrick J, Boylan JC (Eds.), Marcel Dekker, New York-Basel-Hong Kong (1994):165–190.
   Google Scholar
• GRAVES M: Stem cells, haematopoiesis, and leukaemia. In: Introduction to the Cellular and Molecular Biology of Cancer. Franks LM, Teich NM (Eds.), Oxford University Press, London (1997):251–263.
   Google Scholar
• BARRAUD L, MERLE P, SOMA E et al.: Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. HepatoL (2005) 42(5):736–743.
   PubMed Web of Science ®Google Scholar
• SHARMA D, CHELVI TP, KAUR Jet al.: Novel taxol formulation: polyvinylpyrrolidne nanoparticles-encapsulated taxol for drug delivery in
   Google Scholar
• •• cancer therapy. Oncol Res. (1996) 8:281–286.
   Google Scholar
• MITRA S, GAUR U, GOSH PC, MAITRA AN: Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release (2001) 74:317–323.
   PubMed Web of Science ®Google Scholar
• OTSUKA H, NAGASAKI Y, KATAOKA K: PEGylated nanoparticles for biological and pharmaceutical application. Adv. Drug Deliv. Rev. (2003) 55:403–419.
   PubMed Web of Science ®Google Scholar
• MACHIDA Y, ONISHI H, KATO Y, MACHIDA Y: Efficacy of nanoparticles containing irinotecan prepared using poly(DL-lactic acid) and poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) against M5076 tumour in the early liver metastatic stage. STP Pharm. Sci. (2003) 13(4):225–230.
   Google Scholar
• KRISTL J, ALLEMANN E, GURNY R: Formulation and evaluation of zinc-phthalocyanine loaded poly(D,L-lactic acid) nanoparticles. Acta Pharm. (1996) 46:1–12.
   Google Scholar
• LE GAREC D, GORI S, KARKAN D et al.: Preparation, characterisation, cytotoxicity and biodistribution of docetaxel-loaded polymeric micelle formulations. J. DrugDeliv. Sci. Tec. (2005) 15(2):115–120.
   Web of Science ®Google Scholar
• KAKIZAWA Y, KATAOKA K: Block copolymer micelles for delivery of gene and related compounds. Adv. Drug Deliv. Rev. (2002) 54:203–222.
   PubMed Web of Science ®Google Scholar
• ROSLER A, VANDERMEULEN GWM, KLOK HA: Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv. Drug Deliv. Rev. (2001) 53:95–108.
   PubMed Web of Science ®Google Scholar
• •This is a review article on block copolymers.
   Google Scholar
• KANG N, PERRON ME, PRUD'HOMME RE, ZHANG YB, GAUCHER G, LEROUX JC: Stereocomplex block copolymer micelles: core -shell nanostructures with enhanced stability. Nano Letters (2005) 5(2):315–319.
   PubMed Web of Science ®Google Scholar
• BOAS U, HEEGAARD PM: Dendrimers in drug research. Chem. Soc. Rev. (2004) 33:43–63.
   PubMed Web of Science ®Google Scholar
• GILLES ER, FRECHET MJ: Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today (2005) 10(1):35–43.
   PubMed Web of Science ®Google Scholar
• ULBRICH K, SUBR V: Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev. (2004) 56:1023–1050.
   PubMed Web of Science ®Google Scholar
• ZHANG S, XU Y, WANG B, QIA0 W, LIU D, LI Z: Cationic compounds used in lipoplexes and polyplexes for gene delivery. J. Control. Rel. (2004) 100(2):165–180.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-WOLF GD, SCHMIDT-WOLF IG: Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med. (2003) 9(2):67–71.
   PubMed Web of Science ®Google Scholar
• RUBANYI GM: The future of human gene therapy. Mol. Asp. Med. (2001) 22:113–142.
   PubMedGoogle Scholar
• EL-ANEED A: An overview of current delivery systems in cancer gene therapy. J. Control. Release (2004) 94:1–14.
   PubMed Web of Science ®Google Scholar
• CROMMELIN DJ, STORM G, JISKOOT W, STENEKES R, MASTROBATTISTA E, HENNINK WE: Nanotechnological approaches for the delivery of macromolecules. J. Control. Release (2003) 87:81–88.
   PubMed Web of Science ®Google Scholar
• MARCUCCI F, LEFOULON F: Active targeting with particulate drug carriers in tumour therapy: fundamentals and recent progress. Drug Discov. Today (2004) 9(5):219–228.
   PubMed Web of Science ®Google Scholar
• DUNCAN R, CABLE HC, LLOYD JB, REJMANOVA P, KOPECEK J: Polymers containing enzymically degradable bond. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Macromol. Chem. (1983) 184:1997–2008.
   Google Scholar
• KOS J, LAH T: Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol Rep. (1998) 5:1349–1361.
   PubMed Web of Science ®Google Scholar
• HUANG Y, GHANDEHARI H, DUAN YR., ZHANG ZR: HPMA copolymer-mitoxantrone conjugates for targeted cancer chemotherapy. J. Drug Deliv. Sci. Tech. (2004) 14(3):187–191.
   Google Scholar
• VINOGRADOV S: The second annual symposium on nanomedicine and drug delivery: exploring recent developments and assessing major advances. Expert Opin. Drug Deliv. (2004) 1:181–184.
   PubMedGoogle Scholar
• KATAOKA K, MATSUMOTO T, YOKOYAMA M et al.: Doxorubicin-loaded poly(ethylene glycop-poly(13-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J. Control. Release (2000) 64:143–153.
   PubMed Web of Science ®Google Scholar
• THORPE PE, WAWRZYNCZAK EJ, BURROWS FJ: Monoclonal antibodies and therapy. In: Introduction to the Cellular and Molecular Biology of Cancer. Franks LM, Teich NM (Eds.), Oxford University Press, London (1997):353–379.
   Google Scholar
• HUDSON PJ, SOURIAN C: Engineered antibodies. Nat. Med. (2003) 9:129–134.
   PubMed Web of Science ®Google Scholar
• TANAKA T, SHIRAMOTO S, MIYASHITA M, FUJISHIMA Y, KANEO Y: Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. j Pharm. (2004) 277:39–61.
   PubMed Web of Science ®Google Scholar
• NORI A, KOPECEK J: Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Deliv. Rev. (2004) 57(4):609–636.
   PubMed Web of Science ®Google Scholar
• ••This paper presents modifications of polymeric NPs to trigger intracellular vesicles and targets.
   Google Scholar
• GABOR F, WIRTH M: Lectin-mediated drug delivery: fundamentals and perspectives. STP Pharm. Sci. (2003) 13(1):3–16.
   Google Scholar
• BRODSKY FM: New fashions in vesicle coats Trends Cell Biol. (1997)7:175–179.
   Google Scholar
• FONSECA S, SIMOES S, GASPAR R: Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterisation and in vitro anti-tumural activity. J. Control. Release (2002) 83:273–286.
   PubMed Web of Science ®Google Scholar
• CEGNAR M, KOS J, KRISTL J: Cystatin incorporated in poly(lactide-co-glycolide) nanoparticles: development and fundamental studies on preservation of its activity. Eur. J. Pharm. Sci. (2004) 22(5):357–364.
   PubMed Web of Science ®Google Scholar
• RUEFLI AA, JOHNSTONE RW: A role for P-glycoprotein in regulating cell growth and survival. Clin. Appl. Immunol Rev. (2003) 4:31–47.
   Google Scholar
• MINKO T, BATRAKOVA EV, LI S et al.: Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J. Control. Release (2005) 105:269–278.
   PubMed Web of Science ®Google Scholar
• KABANOV AV, BATRAKOVA EV, ALAKHOVVY: Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. (2002) 54:759–779.
   PubMed Web of Science ®Google Scholar
• OWENS J: Stealthy polymers target drug-resistant tumour cells. Drug Discov. Today (2001) 6(11):551–552.
   PubMed Web of Science ®Google Scholar
• MINKO T, KOPECKOVA P, KOPECEK J: Chronic exposure to HPMA copolymer-bound adriamycin does not induce multi-drug resistance in a human ovarian carcinoma cell line. J. Control. Release (1999) 59:133–148.
   PubMed Web of Science ®Google Scholar
• DEBATIN KM: Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother. (2004) 53:153–159.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA N, NORI A, MALUGIN A, KASUYA Y, KOPECKOVA P, KOPECEK J: Free and N-(2-hydroxypropyl) methacrylamide copolymer-bound geldanamycin derivate induce different stress responses in A2780 human ovarian carcinoma cells. Cancer Res. (2003) 63:7876–7882.
   PubMed Web of Science ®Google Scholar
• TURK V KOS J, TURK B: Cysteine cathepsins (proteases) — On the main stage of cancer? Cancer Cell (2004) 5:409–410.
   PubMed Web of Science ®Google Scholar
• PREMZL A, ZAVASNIK-BERGANT V, TURK V KOS J: Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp. Cell Res. (2003) 283(2):206–214.
   PubMed Web of Science ®Google Scholar
• CEGNAR M, PREMZL A. ZAVASNIK-BERGANT V, KRISTL J, KOS J: Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumour cells. Exp. Cell Res. (2004) 301:223–231.
   PubMed Web of Science ®Google Scholar
• •This paper showed an effective inhibition of intracellular proteases using delivery of inhibitor by polymer NPs.
   Google Scholar
• DECOUT A, LABEUR C, GOETHALS M, BRASSEUR R, VANDEKERCKHOVE J, ROSSENEU M: Enhanced efficiency of a targeted fusogenic peptide. Biochimica Biophysica Acta — Biomembranes (1998) 1372:102–116.
   PubMed Web of Science ®Google Scholar
• LUNG WITZ U, BREUNIG M, BLUNK T, GOPFERICH A: Polyethylenimine-based non-viral gene delivery. Eur. j Pharm. Biopharm. (2005) 60(2):247–266.
   PubMed Web of Science ®Google Scholar
• DESHAYES S, MORRIS MC, DIVITA G, HEITZ F: Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Md. Life Sci. (2005) 62:1839–1849.
   PubMed Web of Science ®Google Scholar
• MERDAN T, KOPECEK J, KISSEL T: Prospects for cationic polymers in gene and oliglonucleotiede therapy against cancer. Adv. Drug Deliv. Rev. (2002) 54:715–758.
   PubMed Web of Science ®Google Scholar
• ••This article summarises efforts on theapplication of polyplexes in cancer therapy.
   Google Scholar
• SINHA VR, GOYEL V, TREHAN A: Radioactive microspheres in therapeutics. Pharmazie (2003) 59:419–426.
   Web of Science ®Google Scholar
• BARTH RF, CODERRE JA, VICENTE MG, BLUE TE: Boron neutron capture therapy of cancer: current status and future prospects. Clin. Cancer Res. (2005) 11:3987–4002.
   PubMed Web of Science ®Google Scholar
• •This article presents the current status and future prospects of boron neutron capture therapy of cancer.
   Google Scholar
• NOVAK-DESPOT D, KOS J, SERA G, CEMAZAR M, SKRK J, GUBENSEK F: Boronated CDI 315B monoclonal antibody and its potential use in boron neutron capture therapy. In: Advances in Neutron Capture Therapy (Volume II), Chemistry and Biology Larsen BB, Crawford J, Weinreich R (Eds.), Elsevier Science, Amsterdam, The Netherlands (1997):516–518.
   Google Scholar
• HUANG SM, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of head and neck. Cancer Res. (1999) 59:1935–1940.
   PubMed Web of Science ®Google Scholar
• GLAJCH JL, SINGH P: U56455024 (2002).
   Google Scholar